BERLIN, Germany, April 30, 2024 / Biotech Newswire / -- ProBioGen AG (Berlin/Germany), a premier Contract Development and Manufacturing Organization (CDMO) and technology provider with extensive expertise in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals, and MiGenTra GmbH, a subsidiary of ProBioGen AG and Minapharm Pharmaceuticals SAE (Egypt), today announce a change of management:
Alfred Merz, PhD, has been appointed as Chief Operating Officer effective May 1st, 2024. He follows Dr. Lutz Hilbrich as interim CEO, who is leaving at his own request by a mutual termination agreement. Dr. Alfred Merz joins from BAYER Pharmaceuticals where he held the position of Senior Vice President & Head of Product Supply Medical Devices. Alfred looks back on 30 years international experience in manufacturing, operational excellence and strategy development with leading pharmaceuticals and biotech- companies including Bayer and Novartis in Europe and the USA. He is a certified pharmacist and holds an MBA from St. Gallen University, Switzerland. Dr Lutz Hilbrich joined the company as CEO of ProBioGen AG in June 2020 and is also CEO of its subsidiary MiGenTra GmbH.
Dr. Wafik Bardissi, Chairman of the Supervisory Board of ProBioGen AG and CEO and Chairman of the parent Company Minapharm thanks Dr. Lutz Hilbrich for his contribution over the past years and welcomes Dr. Alfred Merz to lead a sustainable growth strategy at ProBioGen.
Dr. Bardissi commented: “Alfred‘s strategic vision and proven international track record ln Europe and the USA in driving operational excellence, manufacturing and strategy development make him an ideal candidate to prop up ProBioGen’s next phase of innovation and expansion.“
About ProBioGen (Business / Corporate)
ProBioGen is a premiere, Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines with applying proprietary technologies to improve product quality and features. Combining both state-of-the-art development services, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and GMP-compliant manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for almost 30 years. At four locations in Berlin, about 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.
For more information about ProBioGen, follow us on LinkedIn.
Contacts
ProBioGen
Dr. Gabriele Schneider
Chief Business Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
ProBioGen Press Contact
Jana Windt
Head of Marketing and Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Leadership; Appointments and Schedules; Retirement; Manufacturing; Cell Line; Cells, Cultured; cell line development; Germany; ProBioGen AG; MiGenTra GmbH; Minapharm Pharmaceuticals SAE; Change of management; Dr. Alfred Merz; Dr. Lutz Hilbrich; Dr. Wafik Bardissi; Sustainable growth strategy; Expansion
Source: Biotech Newswire